Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) —

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock.

The Company revealed that the offering will amount to $18 million dollars and includes pre-funded warrants.

Benitec Biopharma Inc. is known for its innovative approach to gene therapy, focusing on developing genetic medicines using its unique ddRNAi platform.

How will this affect me?

As a consumer, this announcement may eventually lead to the availability of new and advanced gene therapy treatments that could potentially revolutionize the way certain genetic disorders are treated. It may open up new possibilities for personalized medicine and improved healthcare outcomes.

How will this affect the world?

The developments in gene therapy by companies like Benitec Biopharma Inc. have the potential to have a significant impact on the medical field globally. It can pave the way for more targeted and effective treatments for a wide range of genetic diseases, ultimately contributing to advancements in healthcare on a global scale.

Conclusion:

Benitec Biopharma Inc.’s recent announcement of pricing for its underwritten public offering signifies a step forward in the advancement of gene therapy and genetic medicine. This development has the potential to not only benefit individuals seeking innovative treatments for genetic disorders but also contribute to the evolution of healthcare worldwide.